Deregulation of SOX2-OT is observed in various tumors, including lung cancer [52], gastric cancer [53], esophageal cancer [54], breast cancer [55], hepatocellular carcinoma [56], ovarian cancer [57], pancreatic [58], laryngeal squamous cell carcinoma, osteosarcoma, nasopharyngeal carcinoma, and glioblastoma [59,60]. This evidence concerns the gene SOX2 and esophageal cancer.